Drug Profile
Research programme: eye disorder protein therapeutics - Carisma Therapeutics
Alternative Names: EBI-006; EBI-018; EBI-028; EBI-029Latest Information Update: 08 Mar 2023
Price :
$50
*
At a glance
- Originator Eleven Biotherapeutics
- Developer Carisma Therapeutics
- Class Anti-inflammatories; Eye disorder therapies; Proteins
- Mechanism of Action Interleukin 1 receptor antagonists; Interleukin 17 receptor antagonists; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Age-related macular degeneration; Ocular inflammation; Uveitis
Most Recent Events
- 07 Mar 2023 Sesen Bio has merged with Carisma Therapeutics to form Carisma Therapeutics
- 25 Feb 2022 Roche has patent protection for IL-6 antagonistic, anti-IL6 monoclonal antibodies, and EBI 029 in USA, Australia, China, Japan, Korea, New Zealand, Russia and South Africa (Sesen Bio SEC filing, Form 10-K, March 2022)
- 25 Feb 2022 Roche has patents pending for IL-6 antagonistic, anti-IL6 monoclonal antibodies, and EBI 029 in USA, Brazil, Canada, Europe, India, Mexico and Singapore (Sesen Bio SEC filing, Form 10-K, March 2022)